CoChat

Phenotypic Mapping of Pathologic Cross-Talk between Glioblastoma and Innate Immune Cells by Synthetic Genetic Tracing

Open access
Schmitt, Matthias Jürgen, Company, Carlos, Dramaretska, Yuliia, Barozzi, Iros, Göhrig, Andreas, Kertalli, Sonia, Großmann, Melanie, Naumann, Heike, Sanchez-Bailon, Maria Pilar, Hulsman, Danielle, Glass, Rainer, Squatrito, Massimo, Serresi, Michela, Gargiulo, Gaetano · 2021 · Cancer Discovery
Cited by 92

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Glioblastoma is a lethal brain tumor that exhibits heterogeneity and resistance to therapy. Our understanding of tumor homeostasis is limited by a lack of genetic tools to selectively identify tumor states and fate transitions. Here, we use glioblastoma subtype signatures to construct synthetic genetic tracing cassettes and investigate tumor heterogeneity at cellular and molecular levels, in vitro and in vivo. Through synthetic locus control regions, we demonstrate that proneural glioblastoma is a hardwired identity, whereas mesenchymal glioblastoma is an adaptive and metastable cell state driven by proinflammatory and differentiation cues and DNA damage, but not hypoxia. Importantly, we discovered that innate immune cells divert glioblastoma cells to a proneural-to-mesenchymal transition that confers therapeutic resistance. Our synthetic genetic tracing methodology is simple, scalable, and widely applicable to study homeostasis in development and diseases. In glioblastoma, the method causally links distinct (micro)environmental, genetic, and pharmacologic perturbations and mesenchymal commitment. Significance: Glioblastoma is heterogeneous and incurable. Here, we designed synthetic reporters to reflect the transcriptional output of tumor cell states and signaling pathways' activity. This method is generally applicable to study homeostasis in normal tissues and diseases. In glioblastoma, synthetic genetic tracing causally connects cellular and molecular heterogeneity to therapeutic responses. This article is highlighted in the In This Issue feature, p. 521

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-20-0219

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 92

Metadata

Authors
Schmitt, M. J., Company, C., Dramaretska, Y., Barozzi, I., Göhrig, A., Kertalli, S., Großmann, M., Naumann, H., Sanchez-Bailon, M. P., Hulsman, D., Glass, R., Squatrito, M., Serresi, M., & Gargiulo, G.
Venue
Cancer Discovery
Published
2021-03-01
Volume
11
Issue
3
Pages
754-777
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W3114773357
Cited by
92
References
13
FWCI
4.81
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phenotypic Mapping of Pathologic Cross-Talk between Glioblastoma and Innate Immune Cells by Synthetic Genetic Tracing. https://app.cochat.ai/papers/10.1158/2159-8290.cd-20-0219
The paper
Schmitt, M. J., Company, C., Dramaretska, Y., Barozzi, I., Göhrig, A., Kertalli, S., Großmann, M., Naumann, H., Sanchez-Bailon, M. P., Hulsman, D., Glass, R., Squatrito, M., Serresi, M., & Gargiulo, G. (2021). Phenotypic Mapping of Pathologic Cross-Talk between Glioblastoma and Innate Immune Cells by Synthetic Genetic Tracing. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-20-0219

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.